The short version of research peptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-01. Anything still debated is marked as such rather than presented as settled.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid as supplied |
| Water solubility | Soluble | Dissolves in aqueous media |
| Typical storage temperature | -20 °C | Dry powder, desiccated, protected from light |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity from peak area; mass for identity |
| Common synonyms | Tβ4 fragment; thymosin beta-4 fragment | Naming varies by supplier and catalogue |
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products of the jurisdiction where trial is conducted. (ICH E6) Approval (in relation to institutional review boards (IRBs))
Galloway wrote to the committee saying: "I had nothing to do with any oil deals done by Mr Fawaz Zureikat or anyone else. He and any other company involved were trading on their own behalf". Aziz was also interviewed for the Volcker Committee, but changed his story, which the committee considered unconvincing.
For Bukele to run for president with Nuevas Ideas, he was required to register the party with the Supreme Electoral Court (TSE). Although Nuevas Ideas had enough signatures to register, Bukele believed that the TSE would not register the party before the 29 July 2018 presidential nomination deadline. Bukele registered as a member of Democratic Change and sought the party's presidential nomination before the deadline, but the TSE canceled the party's registration four days before the deadline because Democratic Change failed to receive over 50,000 votes during the 2015 legislative elections. On 29 July 2018, Bukele registered with the right-wing Grand Alliance for National Unity (GANA) and received the party's presidential nomination. He selected Félix Ulloa, a lawyer, as his vice-presidential candidate. Bukele used social media such as Facebook, Instagram, and Twitter extensively throughout his campaign to communicate with his supporters. He did not attend either of the two presidential debates, in December 2018 and January 2019, despite saying that he would attend, claiming that the debate rules were not explained to him. Bukele was the election's front-runner, leading virtually every poll by a substantial margin. His three opponents were ARENA's Carlos Calleja, a businessman who owned the Super Selectos supermarket chain; the FMLN's former minister of foreign affairs Hugo Martínez, and Vamos' Josué Alvarado, a businessman. On election day, 3 February 2019, Bukele defeated Calleja, Martínez, and Alvarado with 53.1 percent of the vote.
=== Arne Magnusson === In Episode Two, Dr. Arne Magnusson (voiced by John Aylward) runs the White Forest base and is described as a Black Mesa survivor. He gets on poorly with Dr. Kleiner due to their clashing personalities, as spelled out by their very names: 'Magnus' means 'great' in Latin, while 'klein' means 'small' in German and Dutch. Magnusson's peculiar personality seems to have gained him much respect from the Vortigaunts, such as his assistant Uriah, who makes awed references to him. Magnusson also makes a remark to Freeman saying that if he successfully defends White Forest, then he will forgive Freeman for an earlier incident in Black Mesa, involving his 'Microwave Casserole', a reference to a scene in the first Half-Life.
Sources: en.wikipedia.org
While protein phosphorylation is a cell-wide regulatory mechanism, recent quantitative proteomics studies have shown that phosphorylation preferentially targets nuclear proteins. Many PPs that regulate nuclear events, are often enriched or exclusively present in the nucleus. In neuronal cells, PPs are present in multiple cellular compartments and play a critical role at both pre- and post-synapses, in the cytoplasm and in the nucleus where they regulate gene expression. Phosphoprotein phosphatase is activated by the hormone insulin, which indicates that there is a high concentration of glucose in the blood. The enzyme then acts to dephosphorylate other enzymes, such as phosphorylase kinase, glycogen phosphorylase, and glycogen synthase. This leads to phosphorylase kinase and glycogen phosphorylase's becoming inactive, while glycogen synthase is activated. As a result, glycogen synthesis is increased and glycogenolysis is decreased, and the net effect is for energy to enter and be stored inside the cell.
=== Psychology === The psychological studies Body Image Concerns of Breast Augmentation Patients (2003) and Body Dysmorphic Disorder and Cosmetic Surgery (2006) indicate that women who seek breast-augmentation surgery usually have a mental-health background that features treatments of psychotherapy, who suffer many occurrences low self-esteem and of psychological depression, in comparison with the general population of women. Moreover, women who sought breast augmentation also suffered body dysmorphia, which is an extreme dissatisfaction and preoccupation with perceived physical defects in her personal appearance, which misperceptions often lead to significant impairment of her mental ability to function socially. Post-operative patient surveys about the mental health and the quality of life of the women, reported improved physical health, physical appearance, social life, self-confidence, self-esteem, and satisfaction with sexual functioning. Furthermore, most of the women reported long-term satisfaction with their breast implants; some despite having had medical complications that required surgical revision, either corrective or aesthetic. In Denmark, 8.0 percent of breast augmentation patients had a pre-operative history of psychiatric hospitalization.
==== Social isolation of people with sickle cell disease ==== The deeply rooted stigma of sickle cell disease in society causes families to often hide their family members' sick status for fear of being labelled, cursed, or left out of social events. Sometimes in Uganda, when it is confirmed that a family member has sickle cell disease, intimate relationships with all members of the family are avoided. The stigmatisation and social isolation that people with sickle cell disease tend to experience are often the consequence of popular misconceptions that people with sickle cell disease should not socialise with those free from the disease. This mentality robs people with sickle cell disease of the right to participate in community activities freely like everyone else. SCD-related stigma and social isolation in schools, especially, can make life for young people living with sickle cell disease challenging. For school-aged children living with sickle cell disease, the stigma they face can lead to peer rejection. Peer rejection involves the exclusion from social groups or gatherings. It often leads the excluded individual to experience emotional distress and may result in their academic underperformance, avoidance of school, and occupational failure later in life. This social isolation is also likely to negatively impact people with sickle cell disease's self-esteem and overall quality of life. Mothers of children with sickle cell disease tend to receive disproportionate amounts of stigma from their peers and family members.
Sources: en.wikipedia.org
=== Off-label drugs === Anticonvulsants (e.g., valproic acid) Atypical antipsychotics (e.g., quetiapine) Azapirones (serotonin 5-HT1A receptor agonists) (e.g., buspirone) Benzodiazepines (GABAA receptor positive allosteric modulators) (e.g., alprazolam, chlordiazepoxide, clonazepam, diazepam, lorazepam) Beta blockers (e.g., propranolol) Gabapentinoids (α2δ subunit-containing voltage-gated calcium channel ligands) (e.g., gabapentin, pregabalin) Monoamine oxidase inhibitors (MAOIs) (e.g., isocarboxazid, moclobemide, phenelzine, tranylcypromine) NMDA receptor antagonists (e.g., ketamine, esketamine) Selective serotonin reuptake inhibitors (SSRIs) (e.g., citalopram, fluvoxamine) Serotonin–norepinephrine reuptake inhibitors (SNRIs) (e.g., desvenlafaxine, duloxetine, levomilnacipran, milnacipran) Serotonin modulators and stimulators (SMSs) (e.g., vilazodone, vortioxetine) Tricyclic antidepressants (TCAs) (e.g., amitriptyline, clomipramine, doxepin, imipramine) Tetracyclic antidepressants (TeCAs) (e.g., mirtazapine) Others (e.g., hydroxyzine)
==== Oral testosterone undecanoate ==== Instead of in its free unesterified form, testosterone is used by oral administration in the form of testosterone undecanoate. Due to the unique chemical properties afforded by its long fatty acid ester chain, this testosterone ester is partially absorbed from the gastrointestinal tract into the lymphatic system, thereby bypassing a portion of first-pass metabolism in the liver and producing measurable increases in testosterone levels at much lower doses than free testosterone. Of oral testosterone undecanoate that reaches circulation, 90 to 100% is transported lymphatically. However, its duration remains short, with an elimination half-life of 1.6 hours and a mean residence time of 3.7 hours. Oral testosterone undecanoate is provided as 40 mg oil-filled capsules and requires administration 2 to 4 times per day (i.e., 80 to 160 mg/day) for substitution in men. It must be taken with food containing at least a moderate or "normal" amount of fat in order to achieve adequate absorption. In addition, there is very high interindividual variability in levels of testosterone with oral testosterone undecanoate. The bioavailability of oral testosterone undecanoate taken with food is 3 to 7%. Inappropriately high levels of testosterone have been observed with 10 to 40 mg/day oral testosterone undecanoate in women. The oral bioavailability of testosterone undecanoate in young women after a single 40 mg dose was found to be 6.8 ± 3.3%.
== External links == Annotated bibliography for Francis Aston from the Alsos Digital Library for Nuclear Issues Francis William Aston on Nobelprize.org including the Nobel Lecture, 12 December 1922 Mass Spectra and Isotopes Aston biography from Cambridge History of Mass Spectrometry - Pioneers
Proprioception is also permanently lost in people who lose a limb or body part through injury or amputation. After the removal of a limb, people may have a confused sense of that limb's existence on their body, known as phantom limb syndrome. Phantom sensations can occur as passive proprioceptive sensations of the limb's presence, or more active sensations such as perceived movement, pressure, pain, itching, or temperature. There are a variety of theories concerning the etiology of phantom limb sensations and experience. One is the concept of "proprioceptive memory", which argues that the brain retains a memory of specific limb positions and that after amputation there is a conflict between the visual system, which actually sees that the limb is missing, and the memory system which remembers the limb as a functioning part of the body. Phantom sensations and phantom pain may also occur after the removal of body parts other than the limbs, such as after amputation of the breast, extraction of a tooth (phantom tooth pain), or removal of an eye (phantom eye syndrome). There is a decline in the sense of proprioception with ageing. This can often result in chronic lower back pain, and be the cause of falls in the elderly.
Sources: en.wikipedia.org
TB-500 is a name used for a short synthetic peptide fragment taken from the actin-binding region of thymosin beta-4. Material sold under this label is usually a lyophilized powder supplied for laboratory research rather than a licensed medicine. The commonly cited sequence is LKKTETQ.
The parent protein contains forty-three amino acids, while the fragment carries only a short motif from one region. The fragment can interact with actin in vitro, but it does not include the rest of the protein structure. Whether the shorter molecule behaves the same way in living systems is not settled.
Published controlled human studies are scarce, and most activity reports come from cell culture or animal models. Reviews often describe the evidence base as limited and methodologically uneven. Open questions include the relationship between route, dose, and measured outcomes.
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.